MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tosetti, F.
Right arrow Articles by Albini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tosetti, F.
Right arrow Articles by Albini, A.

Vol. 63, Issue 3, 565-573, March 2003

N-(4-Hydroxyphenyl)retinamide Inhibits Retinoblastoma Growth through Reactive Oxygen Species-Mediated Cell Death

Francesca Tosetti, Roberta Venè, Giuseppe Arena, Monica Morini, Simona Minghelli, Douglas M. Noonan, and Adriana Albini

Molecular Oncology Laboratory (F.T., R.V., G.A., A.A.), Tumor Progression Section (M.M., D.M.N.), National Cancer Research Institute, and Advanced Biotechnology Center (S.M.), Genova, Italy

Retinoblastoma arises from a subset of developing retinal cells lacking the RB-1 gene product pRB, which have lost the ability to respond to apoptotic signals. A better understanding of retinoblastoma biological response to therapeutic agents with low toxicity could improve the development of novel approaches for treatment and prevention of the disease. Naturally occurring retinoids inhibit growth and induce differentiation of Y79 human retinoblastoma cells in vitro. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) has been shown to induce apoptosis and/or necrosis of tumor cells of neuroectodermal origin. We examined the sensitivity of Y79 retinoblastoma cells to 4HPR in vitro, and in a xenograft model of tumor growth in nude mice in vivo. 4HPR treatment in the range 2.5 to 10 µM induced a loss of Y79 cell viability, as determined by crystal violet, trypan blue exclusion, and long-term clonogenic assays, and impairment of mitochondrial function detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Reactive oxygen species were elevated in 4HPR-treated cells and antioxidants rescued cell viability, indicating that 4HPR-induced cell death was mediated by oxidative stress. 4HPR inhibited growth of Y79 xenografts in vivo in both chemoprevention and intervention settings. Tumor growth inhibition by 4HPR was also associated with significant inhibition of angiogenesis in vivo. These findings could have an important translational value for chemoprevention or early intervention in the treatment of retinoblastoma.

Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
S. Dhakshinamoorthy, S. R. Sridharan, L. Li, P. Y. Ng, L. M. Boxer, and A. G. Porter
Protein/DNA arrays identify nitric oxide-regulated cis-element and trans-factor activities some of which govern neuroblastoma cell viability
Nucleic Acids Res., August 15, 2007; (2007) gkm594v1.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Vene, G. Arena, A. Poggi, C. D'Arrigo, M. Mormino, D. M. Noonan, A. Albini, and F. Tosetti
Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications
Mol. Cancer Ther., January 1, 2007; 6(1): 286 - 298.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi
Clinical trials with retinoids for breast cancer chemoprevention.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L.-H. Yih, Y.-Y. Tseng, Y.-C. Wu, and T.-C. Lee
Induction of Centrosome Amplification during Arsenite-Induced Mitotic Arrest in CGL-2 Cells
Cancer Res., February 15, 2006; 66(4): 2098 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Ferrari, U. Pfeffer, R. Dell'Eva, C. Ambrosini, D. M. Noonan, and A. Albini
The Transforming Growth Factor-{beta} Family Members Bone Morphogenetic Protein-2 and Macrophage Inhibitory Cytokine-1 as Mediators of the Antiangiogenic Activity of N-(4-Hydroxyphenyl)Retinamide
Clin. Cancer Res., June 15, 2005; 11(12): 4610 - 4619.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X. Liao, S. Tang, J. B. Thrasher, T. L. Griebling, and B. Li
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer
Mol. Cancer Ther., April 1, 2005; 4(4): 505 - 515.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Dhakshinamoorthy and A. G. Porter
Nitric Oxide-induced Transcriptional Up-regulation of Protective Genes by Nrf2 via the Antioxidant Response Element Counteracts Apoptosis of Neuroblastoma Cells
J. Biol. Chem., May 7, 2004; 279(19): 20096 - 20107.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics